Literature DB >> 22842340

Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target.

Herman Meurs1, Bart G J Dekkers, Harm Maarsingh, Andrew J Halayko, Johan Zaagsma, Reinoud Gosens.   

Abstract

Since ancient times, anticholinergics have been used as a bronchodilator therapy for obstructive lung diseases. Targets of these drugs are G-protein-coupled muscarinic M(1), M(2) and M(3) receptors in the airways, which have long been recognized to regulate vagally-induced airway smooth muscle contraction and mucus secretion. However, recent studies have revealed that acetylcholine also exerts pro-inflammatory, pro-proliferative and pro-fibrotic actions in the airways, which may involve muscarinic receptor stimulation on mesenchymal, epithelial and inflammatory cells. Moreover, acetylcholine in the airways may not only be derived from vagal nerves, but also from non-neuronal cells, including epithelial and inflammatory cells. Airway smooth muscle cells seem to play a major role in the effects of acetylcholine on airway function. It has become apparent that these cells are multipotent cells that may reversibly adopt (hyper)contractile, proliferative and synthetic phenotypes, which are all under control of muscarinic receptors and differentially involved in bronchoconstriction, airway remodeling and inflammation. Cholinergic contractile tone is increased by airway inflammation associated with asthma and COPD, resulting from exaggerated acetylcholine release as well as increased expression of contraction related proteins in airway smooth muscle. Moreover, muscarinic receptor stimulation promotes proliferation of airway smooth muscle cells as well as fibroblasts, and regulates cytokine, chemokine and extracellular matrix production by these cells, which may contribute to airway smooth muscle growth, airway fibrosis and inflammation. In line, animal models of chronic allergic asthma and COPD have recently demonstrated that tiotropium may potently inhibit airway inflammation and remodeling. These observations indicate that muscarinic receptors have a much larger role in the pathophysiology of obstructive airway diseases than previously thought, which may have important therapeutic implications.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842340     DOI: 10.1016/j.pupt.2012.07.003

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  24 in total

1.  Store-operated calcium entry is required for sustained contraction and Ca2+ oscillations of airway smooth muscle.

Authors:  Jun Chen; Michael J Sanderson
Journal:  J Physiol       Date:  2016-08-02       Impact factor: 5.182

2.  Second M3 muscarinic receptor binding site contributes to bronchoprotection by tiotropium.

Authors:  Loes E M Kistemaker; Carolina R S Elzinga; Christofer S Tautermann; Michael P Pieper; Daniel Seeliger; Suraya Alikhil; Martina Schmidt; Herman Meurs; Reinoud Gosens
Journal:  Br J Pharmacol       Date:  2019-07-02       Impact factor: 8.739

Review 3.  Phenotype-Driven Therapeutics in Severe Asthma.

Authors:  Maria Theresa D Opina; Wendy C Moore
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

Review 4.  QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.

Authors:  James E Frampton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

5.  Can GPCRs Be Targeted to Control Inflammation in Asthma?

Authors:  Pawan Sharma; Raymond B Penn
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  CHRM2 but not CHRM1 or CHRM3 polymorphisms are associated with asthma susceptibility in Mexican patients.

Authors:  Silvia Jiménez-Morales; Juan Luis Jiménez-Ruíz; Blanca Estela Del Río-Navarro; Efraín Navarro-Olivos; Guillermo Escamilla-Guerrero; Ram Savan; Michael Dean; Lorena Orozco
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

Review 7.  Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.

Authors:  Adeeb Bulkhi; Farnaz Tabatabaian; Thomas B Casale
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

8.  Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.

Authors:  Mineo Katsumata; Tomoyuki Fujisawa; Yosuke Kamiya; Yuko Tanaka; Chiaki Kamiya; Yusuke Inoue; Hironao Hozumi; Masato Karayama; Yuzo Suzuki; Kazuki Furuhashi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Masato Maekawa; Mitsutoshi Setou; Hiroshi Watanabe; Koji Ikegami; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2022-05-08       Impact factor: 3.320

Review 9.  Targeting Airway Smooth Muscle Hypertrophy in Asthma: An Approach Whose Time Has Come.

Authors:  Anne Chetty; Heber C Nielsen
Journal:  J Asthma Allergy       Date:  2021-05-25

10.  Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction.

Authors:  Harm Maarsingh; Anouk Oldenburger; Bing Han; Annet B Zuidhof; Carolina R S Elzinga; Wim Timens; Herman Meurs; Ramadan B Sopi; Martina Schmidt
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.